Ratings Moves: HVB,...
Services: Diversified Services
Myriad Genetics Inc. (MYGN: NASDAQ)
$32.24 -0.77 | -2.33%
05/22/13 - 04:00 PM ET
Company Cash Flow
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 112.15M | 100.71M | 152.30M | 84.62M |
| Operating Gains/Losses | -372.00K | -3.00K | 99.00K | 506.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -37.26M | -15.19M | -21.66M | -15.82M |
| (Increase) Decrease in Inventories | -3.43M | 203.00K | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 53.16M | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.25M | 287.00K | -5.31M | -10.71M |
| (Decrease) Increase In Other Current Liabilities | 11.22M | 924.00K | -393.00K | -24.53M |
| (Increase) Decrease In Other Working Capital | 748.00K | -425.00K | 22.00K | -2.00M |
| Other Non-Cash Items | 16.13M | -15.71M | 51.05M | 43.62M |
| Net Cash From Continuing Operations | 141.85M | 130.76M | 155.09M | 84.04M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 141.85M | 130.76M | 155.09M | 84.04M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 52.16M | 111.85M |
| Purchases of Property, Plant & Equipment | -10.26M | -5.79M | -7.90M | -7.52M |
| Acquisitions | -8.80M | -79.42M | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | -477.56M | -308.57M |
| Other Cash from Investing Activities | -17.00M | -100.00K | 356.62M | -2.10M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -38.89M | -54.39M | -76.67M | -206.34M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 25.03M | 25.06M | 22.30M | 84.21M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | -128.47M | -200.49M | -71.39M | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 34.19M | 58.83M | 0.00 | -136.13M |
| Net Cash From Financing Activities | -69.24M | -116.60M | -49.09M | -51.92M |
| Effect of Exchange Rate Changes | -42.00K | 71.00K | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 33.67M | -40.16M | 29.33M | -174.22M |
Portfolios with MYGN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ProJoel Greenblatt - Gotham Ca...
- ContributorStocks Rising On Unusual Vo...
- UserDesNews
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor4 Upgraded, Undervalued Stocks
- Contributor8 Health Care Buys Ahead of...
- ProClovis Capital Management
- ProRS Investment Management
Latest MYGN Headlines from TheStreet
- Myriad Genetics To Announce Third Fiscal Quarter 2013 Results On Tuesday, May 7, 2013 04.18.13 | 04:04 pm
- Myriad Adopts RainDance's Thunderstorm Platform For Next-Generation Sequencing Based Hereditary Cancer Panel 04.17.13 | 04:04 pm
- Myriad Genetics (MYGN) Shares Cross Above 200 DMA 04.15.13 | 05:04 pm
- 3 Stocks Spiking on Big Volume 04.15.13 | 02:04 pm
- Myriad And PharmaMar Announce First Commercial Partnership With Myriad's New HRD Test 03.26.13 | 04:03 pm
- BRCA Testing Granted Preventive Care Designation Under The Affordable Care Act 03.06.13 | 07:03 am
- Myriad's Prolaris(R) Test Predicts Risk Of Prostate Cancer Recurrence In Fourth Peer Reviewed Study 03.05.13 | 07:03 am
- 5 Stocks Pushing The Diversified Services Industry Lower 03.04.13 | 12:03 pm
- Noridian Prices Molecular Pathology Codes; Myriad Confirms Guidance For Fiscal 2013 03.01.13 | 08:03 pm
- 5 Stocks Pushing The Diversified Services Industry Lower 02.12.13 | 12:02 pm
Press Releases for MYGN
- Myriad Genetics Receives The "Corporate Spirit Of Giving Award" From The Utah Philanthropy Day Committee - PR Newswire 11.02.11 | 07:11 am
- Rules-Based Medicine Reaches A Significant Milestone In Companion Diagnostic Program With Roche - PR Newswire 05.25.11 | 04:05 pm
- Rules-Based Medicine, Inc. (RBM) Partners With Institut Pasteur To Boost Innovation In Translational Research - PR Newswire 05.12.11 | 08:05 am
Partner Headlines for MYGN
- US judges cast doubts on DNA patents - Financial Times 04.15.13 | 06:04 pm
- Myriad Says US Supreme Court to Hear Isolated DNA Patent Case - Benzinga 11.30.12 | 04:11 pm
- Testing, Testing: Analyst Kevin DeGeeter On 5 Good Bets In Cancer Diagnostics - Seeking Alpha 11.30.12 | 09:11 am
- Myriad Genetics - Momentum - Zacks 11.20.12 | 01:11 am
- Stocks Tack On More Gains; Cirrus Logic Retakes 200-Day Line - Investor's Business Daily 11.19.12 | 01:11 pm
- Parexel International Leads Medical Research Group - Investor's Business Daily 11.16.12 | 06:11 pm
- Leggett, Sherwin-Williams, DaVita Buck Weak Market - Investor's Business Daily 11.15.12 | 06:11 pm
- Strong 1Q from Myriad, Guidance Up - Analyst Blog - Zacks 11.06.12 | 09:11 am
- Stocks Improve In Late Trade; Nationstar Pares Losses - Investor's Business Daily 11.05.12 | 03:11 pm
- Myriad Remains Neutral - Analyst Blog - NASDAQ 09.21.12 | 07:09 pm
